Age and the residual risk of cardiovascular disease following low density lipoprotein-cholesterol exposure
AbstractWe believe that there is sufficient evidence from basic science, longitudinal cohort studies and randomised controlled trials which validates the low-density lipoprotein cholesterol (LDL–C) or lipid hypothesis. It is important that we can communicate details of the cardiovascular disease (CVD) risk reduction that the average patient could expect depending on the scale of LDL–C decrease following lipid lowering therapy. It is also essential that residual risk (ResR) of CVD be highlighted.
To achieve this aim by using existing trial evidence, we developed mathematical models initially for relative risk reduction (RRR) and absolute risk (AR) reduction and then showed that despite optimising LDL–C levels, a considerable degree of ResR remains that is dependent on AR. Age is significantly associated with AR (odds ratio 1.02, 95% confidence intervals 1.01–1.04) as was previously demonstrated by analysing the Whickham study cohort using a logistic regression model (age remaining significant even when all the other significant risk factors such as sex, smoking, systolic blood pressure, diabetes and family history were included in the regression model).
A discussion of a paper by B.A. Ference et al. provided detailed evidence of the relationship between age and AR, based on lifetime LDL–C exposure. Finally, we discussed non-traditional CVD risk factors that may contribute to ResR based on randomised controlled trials investigating drugs improving inflammation, thrombosis, metabolic and endothelial status.
Keywords:mathematical modelling; residual cardiovascular risk; age and cardiovascular disease; low density lipoprotein cholesterol exposure; non-LDL–C cardiovascular risk factors
König C.S., Mann A., McFarlane R., Marriott J., Price M., Ramachandran S. Age and the residual risk of cardiovascular disease following low density lipoprotein-cholesterol exposure. Biomedicines. 2023; 11: 3208. DOI: https://doi.org/10.3390/biomedicines11123208
References
1. Cardiovascular Diseases (CVDs) – World Health Organisation 11 June 2021. URL: www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (date of access May 14, 2023).
2. Timmis A., Kazakiewicz D., Torbica A., Townsend N., Huculeci R., Aboyans V., et al. Cardiovascular disease care and outcomes in West and South European countries. Lancet Reg Health Eur. 2023; 33: 100718.
3. Tsao C.W., Ramachandran V.S. Cohort Profile: the Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology. Int J Epidemiol. 2015; 44: 1800–13.
4. Anderson K.M., Wilson P.W., Odell P.M., Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83: 356–62.
5. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002; 105: 310–5.
6. SCORE 2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE 2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42: 2439–54.
7. SCORE 2-OP Working Group and ESC Cardiovascular Risk Collaboration. SCORE 2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42; 2455–67.
8. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007; 335: 136.
9. Ramachandran S., Bhartia M., König C.S. The lipid hypothesis: from resins to Proprotein Convertase Subtilisin/Kexin Type-9 inhibitors. Front. Cardiovasc. Drug Discov. 2020; 5: 48–81.
10. Toft-Nielsen F., Emanuelsson F., Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022; 13: 840797.
11. Sharifi M., Rakhit R.D., Humphries S.E., Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart. 2016; 102: 1003–8.
12. Board J. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS 3). Heart. 2014; 100 (suppl S 2): ii1–67.
13. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251: 351–64.
14. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670–81.
15. Baigent C., Landray M.J., Reith C., Emberson J., Wheeler D.C., Tomson C., et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181–92.
16. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Théroux P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387–97.
17. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376: 1713–22.
18. Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379: 2097–107.
19. Ramachandran S., French J.M., Vanderpump M.P., Croft P., Neary R.H. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ. 2000; 320: 676–7.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–9.
21. Ference B.A., Graham I., Tokgozoglu L., Catapano A.L. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018; 72: 1141–56.
22. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195–207.
23. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495–504.
24. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377: 1119–31.
25. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849–60.
26. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791–800.
27. Steg P.G., Bhatt D.L., Simon T., Fox K., Mehta S.R., Harrington R.A., et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019; 381: 1309–20.
28. Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9–19.
29. Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319–30.
30. Paré G., Çaku A., McQueen M., Anand S.S., Enas E., Clarke R., et al.; INTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019; 139: 1472–82.
31. Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380: 11–22.
32. Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371: 2383-93.
33. AIM-HIGH Investigators; Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-67.
34. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J.P., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357: 2109-22.
35. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317: 1237-45.
36. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341: 410-8.
37. BIP STUDY GROUP. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000; 102: 21-7.
38. Keech A.C., Simes R.J., Barter P.J., Best J.D., Scott R.A.P., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849-61.
39. ACCORD Study Group; Ginsberg H.N., Elam M.B. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-74.
40. Bruckert E., Labreuche J., Deplanque D., Touboul P.J., Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011; 57: 267-72.
41. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-28.
42. Yusuf S., Sleight P., Pogue J.F., Bosch J., Davies R., Dagenais G.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000; 342: 145-53.
43. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-9.
44. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353: 611-6.
45. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338: 645-52.
46. König C.S., Atherton M., Cavazzuti M., Gomm C., Ramachandran S. The association of peak systolic velocity in the carotid artery with coronary heart disease: a study based on portable ultrasound. Proc Inst Mech Eng H. 2021; 235: 663-75.
47. Dhindsa D.S., Sandesara P.B., Shapiro M.D., Wong N.D. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. 2020; 7: 88.
48. Shipman K.E., Strange R.C., Ramachandran S. Use of fibrates in the metabolic syndrome: a review. World J Diabetes. 2016; 7: 74-88.
49. Jun M., Foote C., Lv J., Neal B., Patel A., Nicholls S.J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375: 1875-84.
50. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-06.
51. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-57.
52. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311-22.
53. Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834-44.
54. Hernandez A.F., Green J.B., Janmohamed S., D’Agostino R.B. Sr, Granger C.B., Jones N.P., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392: 1519-29.
55. Chhabra N. Endothelial dysfunction - a predictor of atherosclerosis. Internet J Med. Update. 2009; 4: 33-41.
56. Peiffer V., Sherwin S.J., Weinberg P.D. Does low and oscillatory wall shear stress correlate spatially with early atherosclerosis? A systematic review. Cardiovasc Res. 2013; 99: 242-50.
57. Zhou J., Li Y.S., Chien S. Shear stress-initiated signaling and its regulation of endothelial function. Arterioscler Thromb Vasc Biol. 2014; 34: 2191-8.
58. Srikanth S., Deedwania P. Management of dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Curr Hypertens Rep. 2016; 18: 76.
59. Anderson S.G., Hutchings D.C., Woodward M., Rahimi K., Rutter M.K., Kirby M., et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016; 102: 1750-6.
60. Andersson D.P., Lagerros Y.T., Grotta A., Bellocco R., Lehtihet M., Holzmann M.J. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017; 103: 1264-70.
61. Hackett G., Heald A.H., Sinclair A., Jones P.W., Strange R.C., Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE 5Inhibitors and statins. Int J Clin Pract. 2016; 70: 244-53.
62. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41: 111-88.
63. Contois J.H., Langlois M.R., Cobbaert C., Sniderman A.D. Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol. J Am Heart Assoc. 2023; 12: e030405.
64. Ramachandran S., König C.S., Hackett G., Livingston M., Strange R.C. Managing clinical heterogeneity: an argument for benefit-based action limits. J Med Diagn Ther. 2018; 1: 034701.
65. Missen F., Nicholls S., Sipahi I.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295: 1556-65.
66. Nicholls S.J., Borgman M., Nissen S.E., Raichlen J.S., Ballantyne C., Barter P., et al. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011; 27: 1119-29.
67. Dawson L.P., Lum M., Nerleker N., Nicholls S.J., Layland J. Coronary atherosclerotic plaque regression: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022; 79: 66-82.